METEOR Trial Reports on the Effect of Rosuvastatin on Progression of Carotid Intima-Media Thickness in Low-Risk Individuals with Subclinical Atherosclerosis

Log in or subscribe to view full content.
Article is also available for purchase the article in one of the available formats.
Rudy M. Haddad, MD and Christie M. Ballantyne, MD

Table of Contents

Physician and Sportsmedicine:

Volume 38 No. 2

Category:

Practice Pearls

Purchase this article in one of the formats specified below:

DOI: 10.3810/psm.2010.06.1797
Abstract: PRACTICE PEARLThe data from the METEOR trial show that asymptomatic low-risk patients treated with rosuvastatin have a reduction in progression of carotid intima-media thickness (CIMT) over 2 years versus placebo.Original ArticleCrouse JR 3rd, Raichlen JS, Riley WA, et al; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007;297(12):1344–1353.

Keywords: rosuvastatin , low risk , subclinical atherosclerosis , carotid intima-media thickness